Experimental Drug Shows Promise in Stopping Alzheimer's Before Symptoms Appear

Revolutionary Approach to Early Intervention

Northwestern University scientists have developed an experimental drug that shows remarkable promise in halting Alzheimer's disease before memory loss begins, marking a potential breakthrough in treating the devastating condition . The drug, called NU-9, demonstrated its ability to significantly lower levels of toxic protein molecules called amyloid beta oligomers in mouse models, which can aggregate into the harmful plaque clumps associated with Alzheimer's .

The research addresses a critical challenge in Alzheimer's treatment: the disease begins decades before symptoms appear, with toxic protein buildup occurring long before memory loss becomes apparent, and by the time symptoms emerge, the underlying pathology is already advanced . In this study, researchers administered NU-9 before symptom onset, modeling the early, pre-symptomatic window when intervention might be most effective .

Targeting a Newly Discovered Culprit

Northwestern scientists identified a previously unknown highly toxic sub-species of amyloid beta oligomers that appear to drive several of the brain's earliest changes, including neuronal dysfunction, inflammation and activation of immune cells . The team discovered that NU-9 targets a subtype of amyloid beta oligomers they called ACU193+, which was found to spearhead the cascade of inflammation that activates neurodegenerative processes long before cognitive symptoms become evident .

With NU-9 deployed, far fewer of these toxic oligomers were detected in mouse brains, which in turn kept brain support cells called astrocytes in a calmer, healthier state . The treatment also sharply reduced early reactive astrogliosis, an inflammatory process that damages astrocytes and drives neuroinflammation during the earliest stages of Alzheimer's disease .

From Lab Success to Clinical Promise

Conceived about 15 years ago, NU-9 emerged from efforts to discover compounds that could prevent toxic protein buildup in neurodegenerative diseases, and by 2021, it demonstrated efficacy in animal models of ALS, receiving FDA clearance in 2024 to begin human clinical trials for that condition . In previous studies, NU-9 showed it could clear toxic amyloid beta oligomers in lab-grown brain cells from the hippocampus, a region critical for learning and memory .

As one researcher explained, cells have a mechanism to get rid of toxic proteins, but it gets damaged in degenerative diseases like ALS and Alzheimer's, and NU-9 appears to be rescuing the pathway that saves the cell . The results have been described as "stunning" by the research team .

A Preventive Medicine for the Brain

If all goes as hoped, NU-9 could become a preventative treatment taken by people at high risk of developing Alzheimer's later in life, similar to how cholesterol-lowering drugs are used to reduce heart disease risk . If someone has a biomarker signaling Alzheimer's disease, they could potentially start taking NU-9 before symptoms appear, and with early diagnostic blood tests for Alzheimer's in development, the combination of better diagnostics and a drug that could stop the disease represents the ultimate goal .

Currently, the team is testing NU-9 in additional models of Alzheimer's disease, including an animal model of late-onset disease that better reflects typical human aging . While human trials for Alzheimer's haven't begun yet, the drug's success in ALS trials and these promising preclinical results suggest a potential paradigm shift toward treating neurodegeneration before it causes irreversible damage.